PTC/SB/08s (08-03)
Approved for use through 97/31/2006, 0NE 0851-0231
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number.

Application Number

Filing Date

STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)				First I	First Named Inventor KHOMYNETS, Znoviy				Dmitrievich				
				Art Ur	Art Unit							_	
				Exam	iner Na	me							
				Attorr	ey Doc	ket Numb	er	V-338					
					U.S.I	PATENTS				Remove			
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue [Date	Name of Patentee or Applicant Re			Relev	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1	4744730		1988-0	5-17	Roeder							
	2	4293283		1981-1	0-06	Roeder							
If you wish	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click	the A	dd button.	_	Add			
			U.S.P	ATENT	APPLIC	CATION P	UBLI	CATIONS		Remove		-	
Examiner Initial*	xaminer Cite No Publication Number Kind Code1				Publication Date Name of Patentee or of cited Document				Relev	,Columns, ant Passaç es Appear	Lines where ges or Relev	vant	
If you wish	1 h to a	dd additional U.S. Publ	ished Ap	-			_		d buttor	Add Remove		_	
				FOREI	GN PAT	ENT DOC	UME	NTS	_				
Examiner Initial*	Cite No	Foreign Document Number ³		Country Code ² i		Publicatio Date	Name of Patentee Applicant of cited Document				evant or Relevant		
	1	2121610	RU					Khominets					
	2	2059891	RU				Τ,	vano-Frankovsy Ir	estitut			П	

	Application Number		
NEODIA TION DIOOL COURT	Filing Date		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	KHO	MYNETS, Zinoviy Dmitrievich
(Not for submission under 37 CFR 1.99)	Art Unit		
,	Examiner Name		
	Attaces Dealest North		V 228

If you wisl	h to a	dd add	ditional Foreig	n Patent D	Ocumen	nt citation	n inforr	nation pleas	e click the Add	button	Add		
				NO	N-PATE	ENT LIT	ERAT	IRE DOCU	MENTS		Remov	9	
Examiner Initials*	Cite No	(bool		journal, ser	rial, sym	nposium,	catalo		article (when a , pages(s), vol				tem T ^o
	1												
If you wis	h to a	dd add	ditional non-p	tent literat	ture doc	ument c	itation	nformation	please click the	Add b	utton A	dd	
					E	XAMINE	ER SIG	NATURE					
Examiner	Signa	ture							Date Conside	ered			
									ance with MPE				gh a

1 See Kin Codes of USPTO Patent Documents at wear USPTO_GOLY or MPEP 90.16. If Enter office that seased the document, by the low-left or potential patent patent document, by the low-left or potential patent document, and or patent document. A find of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. If Applicant is to place a check mark here if English language the resistation is attached.

Application Number Filing Date Filing Date STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Application Number Filing Date F

CERTIFICATION STATEMENT

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement was called the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement are filing the certification and filing the filing the filing the filing that the filing the filing the filing that the filing that

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

.7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

ionii oi tilo signataro.			
Signature	/james h walters/	Date (YYYY-MM-DD)	2006-05-07
Name/Print	James H. Walters	Registration Number	35731

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, U.S. operationed for Commence, P. 0. Bot 1450, Alexandria, V.S. 2213.1-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.2313.1-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the state of the s
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.